Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of re-operation on survival in patients with recurrent glioblastoma.
Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, Pozzati E, Galzio R, Talacchi A, Volpin L, Morandi L, Danieli D, Ermani M, Brandes AA. Franceschi E, et al. Among authors: tosoni a. Anticancer Res. 2015 Mar;35(3):1743-8. Anticancer Res. 2015. PMID: 25750337
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M; Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes AA, et al. Among authors: tosoni a. J Clin Oncol. 2004 May 1;22(9):1598-604. doi: 10.1200/JCO.2004.11.019. J Clin Oncol. 2004. PMID: 15117981 Clinical Trial.
Treatment of brain metastases in uncommon tumors.
Tosoni A, Lumachi F, Brandes AA. Tosoni A, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):783-93. doi: 10.1586/14737140.4.5.783. Expert Rev Anticancer Ther. 2004. PMID: 15485313 Review.
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M. Brandes AA, et al. Among authors: tosoni a. J Clin Oncol. 2004 Dec 1;22(23):4779-86. doi: 10.1200/JCO.2004.06.181. J Clin Oncol. 2004. PMID: 15570079 Clinical Trial.
274 results